2023-02-27-Evaluate_Vantage-Biopharma_and_Medtech_Review_2022_36页_523kb

Biopharma and Medtech Review 2022 by Evaluate Vantage discusses market trends, IFCs, and M&A activity in the pharma and medtech sectors as of Q4 2022. Notably, small-cap biotechs saw losses in 2022, while large-caps gained value late in the year. Key drivers included Merck's Keytruda developments, Daikyo's pipeline wins, and significant buyouts like Amgen's Horizon acquisition. The biopharma IPO market remained challenging, marked by depressed valuations and funding difficulties. Venture capital activity reached 2019 levels in Q4 but showed signs of fatigue. Overall, the market characterized a recovery for large-caps while mid and small-cap firms faced substantial pressure.

Medtech experienced a stock market decline with most indices showing negative returns. Big-cap firms saw varied performance, with Abiomed and Boston Scientific as standouts. The sector's M&A activity was limited in volume but marked by Johnson & Johnson's large acquisition. The venture environment saw reduced investment activity in late 2022, though funding continued in early planning phases. Both biopharma and medtech IPO activity decreased significantly in late 2022 and saw price discount during flotation. Approval trends showed delays, with PMAs taking longer than in recent years.

Additional topics covered include competitive intelligence tools for market analysis and sector data services offered by Evaluate.